Welcome to our dedicated page for AstraZeneca news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on AstraZeneca stock.
AstraZeneca PLC (AZN) generates a steady flow of news driven by its global biopharmaceutical activities in Oncology, Rare Diseases and BioPharmaceuticals. Company announcements frequently cover clinical trial milestones, regulatory decisions, manufacturing investments and strategic collaborations, offering investors and healthcare professionals insight into how its pipeline and marketed medicines are evolving.
Recent news highlights include multiple updates on Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan), two antibody drug conjugates jointly developed with Daiichi Sankyo. These stories describe new Phase 3 trials, Breakthrough Therapy Designations, and approvals in indications such as HER2-positive early breast cancer, metastatic breast cancer, HER2-expressing endometrial cancer and HER2-expressing ovarian cancer, as well as TROP2-directed approaches in lung and breast cancer.
News items also cover immuno-oncology developments with Imfinzi (durvalumab), including perioperative regimens for gastric and gastroesophageal junction cancers based on the MATTERHORN trial, and broader use in gastrointestinal and thoracic malignancies. In Rare Diseases and immunology, AstraZeneca reports on approvals for Koselugo in adult NF1-associated plexiform neurofibromas and on expanded administration options for Saphnelo in systemic lupus erythematosus.
Beyond clinical and regulatory updates, AstraZeneca’s news feed includes information on large-scale manufacturing investments in the United States, such as expansion of biologics facilities in Maryland, and technology partnerships like the selection of Salesforce’s Agentforce Life Sciences platform for AI-powered customer engagement. Visitors to this AZN news page can review these developments to understand how AstraZeneca’s pipeline, approvals and infrastructure may influence its long-term strategic direction.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo announced that the FDA has accepted their supplemental Biologics License Application (sBLA) for ENHERTU® followed by THP for review in high-risk HER2-positive early-stage breast cancer patients prior to surgery.
The application is based on the DESTINY-Breast11 phase 3 trial, which demonstrated statistically significant improvements in pathologic complete response (pCR) rates compared to standard treatment. The trial also showed an improved safety profile and early positive trend in event-free survival. The FDA target action date is set for May 18, 2026.
This potential approval could represent a new treatment approach for patients with high-risk HER2-positive early-stage breast cancer, where currently nearly half of patients don't achieve pCR with existing neoadjuvant treatments.
AstraZeneca (NYSE:AZN) announced positive results from the DESTINY-Breast05 Phase III trial, showing that ENHERTU demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival (IDFS) compared to T-DM1 in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment.
This marks the second positive Phase III trial for ENHERTU in HER2-positive early breast cancer, following earlier success in the DESTINY-Breast11 trial. The safety profile remained consistent with known data, with no new concerns identified. Overall survival data was not mature at this interim analysis.
The results will be presented at ESMO 2025 in a Presidential Symposium, and data will be shared with global regulatory authorities. The trial was conducted in collaboration with major research groups including NSABP Foundation, German Breast Group, AGO-B, and SOLTI.
AstraZeneca (NYSE:AZN) announced positive topline results from the DESTINY-Breast05 phase 3 trial of ENHERTU® in HER2-positive early breast cancer patients. The trial demonstrated a highly statistically significant and clinically meaningful improvement in invasive disease-free survival compared to T-DM1 in patients with residual disease after neoadjuvant treatment.
This marks the second positive phase 3 trial for ENHERTU in HER2-positive early breast cancer, following successful DESTINY-Breast11 results earlier this year. The safety profile remained consistent with previous findings, with no new concerns identified. Both trials' results will be presented at ESMO 2025's Presidential Symposium, and regulatory submissions are currently being prepared.
AstraZeneca (NYSE:AZN) has announced the launch of AstraZeneca Direct, a new direct-to-consumer online platform that will provide eligible US patients with access to prescribed medications at reduced prices with home delivery. Starting October 1, 2025, patients can purchase medicines like AIRSUPRA and FARXIGA at up to 70% off list price, along with FLUMIST for home delivery.
The platform aims to support patients with chronic conditions such as asthma, diabetes, heart failure, and chronic kidney disease, as well as those seeking flu protection. This initiative complements AstraZeneca's existing patient support services, which will continue unchanged for eligible patients, offering medications at no or reduced cost.
AstraZeneca (NYSE:AZN) and Daiichi Sankyo announced that their ENHERTU plus pertuzumab combination therapy has received Priority Review from the FDA for first-line treatment of HER2-positive metastatic breast cancer. The decision is based on the groundbreaking DESTINY-Breast09 Phase III trial results, which demonstrated a 44% reduction in disease progression or death risk compared to standard treatment.
The trial achieved a remarkable median progression-free survival of 40.7 months with ENHERTU plus pertuzumab versus 26.9 months for the current standard treatment. The combination therapy showed an impressive 85.1% objective response rate with 58 complete responses. The FDA's decision is expected in Q1 2026, potentially establishing a new standard of care in the first-line setting where approximately 10,000 patients are treated annually in the US.
AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo announced that their supplemental Biologics License Application (sBLA) for ENHERTU® plus pertuzumab has received Priority Review from the FDA for first-line treatment of HER2 positive metastatic breast cancer.
The application is supported by the DESTINY-Breast09 phase 3 trial results, which demonstrated that ENHERTU plus pertuzumab reduced disease progression or death risk by 44% compared to standard treatment. The median progression-free survival reached 40.7 months versus 26.9 months for the control group, with an impressive 85.1% objective response rate.
The FDA target action date (PDUFA) is set for January 23, 2026. If approved, this ENHERTU-based treatment could become the new standard of care in first-line HER2 positive metastatic setting, marking the first major evolution in this treatment setting in over a decade.
SOPHiA GENETICS (Nasdaq: SOPH) has expanded its collaboration with AstraZeneca to enhance breast and prostate cancer detection through advanced AI technology. The partnership focuses on developing an optimized next-generation sequencing (NGS) solution that employs AI algorithms to detect genetic mutations in the PIK3CA/AKT1/PTEN pathway.
The companies have already developed a prototype demonstrating improved sensitivity in mutation detection. SOPHiA GENETICS will implement a Privileged Access Program for selected clinical laboratories, with broader commercial availability expected in 2026. The program includes a multi-center real-world evidence study to validate the technology's effectiveness in clinical settings.
AstraZeneca (NYSE:AZN) announced that the FDA has approved an updated US prescribing information for AIRSUPRA® to include data from the BATURA Phase IIIb trial in mild asthma patients. The study demonstrated that AIRSUPRA significantly reduced the risk of severe exacerbations by 46% compared to albuterol in adult patients with mild asthma.
The BATURA trial results, published in the New England Journal of Medicine, showed positive outcomes including reduced annualized severe exacerbation rates and systemic steroid dose. AIRSUPRA maintains its position as the first and only FDA-approved anti-inflammatory rescue medication for as-needed treatment of bronchoconstriction and exacerbation risk reduction in asthma patients aged 18 and older.
AstraZeneca (NYSE:AZN) announced positive interim results from its Phase III TULIP-SC trial evaluating SAPHNELO's subcutaneous administration for systemic lupus erythematosus (SLE) treatment. The trial demonstrated statistically significant and clinically meaningful reduction in disease activity compared to placebo, with a safety profile consistent with its intravenous formulation.
The study involved 367 participants with moderately to severely active, autoantibody-positive SLE, randomized 1:1 to receive either 120mg subcutaneous SAPHNELO or placebo weekly. The interim analysis was conducted when the first 220 participants reached week 52. This new administration method could potentially expand access to SAPHNELO, which is currently approved in over 70 countries and has treated more than 38,000 patients globally.
AstraZeneca (NASDAQ:AZN) announced that the European Medicines Agency (EMA) has validated their Type II Variation application for ENHERTU® for treating adult patients with HER2 positive metastatic solid tumors. The application is supported by data from three phase 2 trials: DESTINY-PanTumor02, DESTINY-CRC02, and DESTINY-Lung01.
If approved, ENHERTU would become the first HER2 directed medicine and antibody drug conjugate to receive a tumor agnostic indication in the EU. The treatment targets patients who have received prior treatment and have no satisfactory alternative treatment options.